TerminatedPhase 2NCT00003156
Topotecan in Treating Patients With Recurrent or Refractory Cancer of the Uterus
Studying Carcinosarcoma of the corpus uteri
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Gynecologic Oncology Group
- Principal Investigator
- David S. Miller, MDSimmons Cancer Center
- Intervention
- topotecan hydrochloride(drug)
- Eligibility
- FEMALE
- Timeline
- 1998
Study locations (30)
- University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States
- Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
- Community Hospital of Los Gatos, Los Gatos, California, United States
- Chao Family Comprehensive Cancer Center, Orange, California, United States
- Walter Reed Army Medical Center, Washington D.C., District of Columbia, United States
- H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
- Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States
- University of Chicago Cancer Research Center, Chicago, Illinois, United States
- Indiana University Cancer Center, Indianapolis, Indiana, United States
- University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
- Radiation Oncology Branch, Bethesda, Maryland, United States
- Tufts University School of Medicine, Boston, Massachusetts, United States
- Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
- University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
- University of Mississippi Medical Center, Jackson, Mississippi, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00003156 on ClinicalTrials.govOther trials for Carcinosarcoma of the corpus uteri
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07029399A Study With NKT5097 for Adults With Advanced/Metastatic Solid TumorsNiKang Therapeutics, Inc.
- RECRUITINGPHASE2NCT05619913EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine CarcinosarcomaAustralia New Zealand Gynaecological Oncology Group
- ACTIVE NOT RECRUITINGPHASE2NCT05147558A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine CarcinosarcomaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1, PHASE2NCT03686124ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid TumorsImmatics US, Inc.